How Marijuana Stocks Work: MSOs, Canadian LPs, Ancillary Firms, REITs and ETFs
This guide is for hemp growers, small-business owners and everyday investors who keep hearing about “marijuana stocks” and want to know what is actually behind the label. You will learn the main types of public cannabis companies, how federal law shapes where their shares trade, what changed after the April 2026 rescheduling order, and which risks come with each type. It names companies only as neutral examples and makes no recommendations.
This article is for education only and is not investment, legal, or tax advice. Investing involves risk, including loss of principal.
- “Marijuana stocks” covers at least five different business types: U.S. multi-state operators (MSOs), Canadian licensed producers, ancillary suppliers, cannabis-focused REITs and lenders, and ETFs.
- As of November 19, 2026, only marijuana in FDA-approved drugs or held under a state medical license is in Schedule III. Adult-use (recreational) marijuana is still Schedule I.
- That split matters for listings. Companies that touch adult-use marijuana have generally traded on Canadian exchanges and U.S. over-the-counter markets rather than the NYSE or Nasdaq.
- Thin trading, limited clearing, heavy taxes and fast-moving rules make this one of the riskiest corners of the market.
Table of Contents
Why cannabis stocks are a special case
Most industries have one set of federal rules. Cannabis has two layers that disagree. Dozens of states license marijuana businesses, but the federal Controlled Substances Act (CSA) has long listed marijuana in Schedule I, the most restrictive category. That conflict touches nearly everything a public company needs: bank accounts, stock exchange listings, brokers willing to clear trades, and the tax code.
The federal picture shifted in 2026, but only partly. On April 28, 2026, the Justice Department published a final order in the Federal Register moving two narrow groups into Schedule III: FDA-approved drug products containing marijuana, and marijuana held under a state-issued medical marijuana license. The same order says that any other form of marijuana remains in Schedule I. A separate DEA proceeding on moving all marijuana to Schedule III was still pending as of November 19, 2026, and no final rule from it had been published. Our explainer on rescheduling and 280E covers that process in detail.
For investors, the result is that two companies both described as “cannabis” can sit in very different legal positions. A medical-only operator in a medical-only state, an operator selling adult-use products in several states, and a Canadian producer are three separate risk profiles.
The SEC has long warned that fraudsters use popular industries to sell schemes. Its 2018 investor alert on marijuana investments pointed to trading suspensions, frequent name or business-plan changes, and implausible press releases as warning signs, especially in thinly traded microcap stocks. It also reminded investors that some marijuana-related businesses could face criminal prosecution. Those warnings still describe the bottom of this market well.
U.S. multi-state operators (MSOs)
An MSO grows, processes and sells marijuana under state licenses in more than one state. Many are “vertically integrated,” meaning the same company runs cultivation, manufacturing and retail dispensaries. Because each state licenses separately and products generally cannot cross state lines, an MSO is really a bundle of state-level businesses under one holding company.
Key features of the MSO model:
- State-by-state economics. Revenue depends on how many licenses a state issues, local pricing, and whether the state is medical-only or also allows adult use.
- Heavy federal tax. Until 2026, every plant-touching marijuana business faced IRC Section 280E, which blocks deductions and credits for businesses trafficking in Schedule I or II substances. Medical licensees now argue they are outside 280E; adult-use businesses are still inside it.
- Cross-border corporate structures. Some large MSOs were organized in Canada and listed on the Canadian Securities Exchange (CSE), with U.S. trading on the OTC markets. One large operator’s 2025 annual report (Form 10-K), for example, described its shares as listed on the CSE and quoted in the U.S. on the OTCQX Best Market.
- Dependence on non-bank capital. Limited access to banks and exchanges has pushed MSOs toward private notes, sale-leasebacks and specialty lenders.
The April 2026 order created a new path for medical operators. It set up an expedited DEA registration process for holders of state medical licenses. Applicants who filed within 60 days of publication were to have their applications processed within six months and could keep operating under their state licenses while DEA reviewed them. Read each company’s filings to see whether it applied, and how much of its business is medical versus adult-use.
Canadian licensed producers
Canada legalized adult-use cannabis nationally. According to the official consolidated text of the federal Cannabis Act, most of its provisions came into force on October 17, 2018. Producers there need federal licences, and they operate under a national framework rather than a patchwork of state rules.
That legal footing is the key difference from an MSO: a Canadian producer’s core cannabis activity is lawful under the national law where it takes place, which gives it more listing and financing options. Legal status is not the same as profitability, though. The Act’s stated purpose centers on public health and safety, including limits on promotion and youth access, so producers work within federal rules on how products are marketed and sold. When you read a Canadian producer’s reports, look at how much revenue comes from cannabis versus other business lines, and at inventory write-downs.
If a Canadian or U.S.-listed company describes a path into the U.S. adult-use market, read exactly how it is structured. Arrangements that only close or convert if U.S. federal law or exchange rules change are bets on future policy, not current revenue.
Ancillary companies
Ancillary companies sell to the cannabis industry without growing or selling marijuana themselves. Examples include makers of hydroponic and lighting equipment, packaging suppliers, testing labs, compliance-software vendors, and payment or point-of-sale providers. Because they do not “touch the plant,” they generally face fewer federal barriers to banking and exchange listing.
The trade-off is indirect exposure. An ancillary firm’s results depend on its customers’ capital budgets. When cannabis prices fall and operators cut spending, equipment and supply sales can drop quickly. Ancillary companies also sell into other markets (general agriculture, food, or hemp), so check the revenue breakdown before treating one as a cannabis business. Hemp farmers will recognize many of these suppliers from their own equipment purchases.
REITs and specialty lenders
Investor.gov explains that a real estate investment trust (REIT) owns or finances income-producing real estate, and that publicly traded REITs differ in liquidity and transparency from non-traded REITs. In cannabis, two REIT models have appeared:
- Property REITs buy cultivation facilities and dispensaries, often in sale-leaseback deals, and lease them back to licensed operators on long-term, triple-net terms. One such REIT describes this model in its 2025 10-K.
- Mortgage REITs and lenders make loans to cannabis operators secured by real estate and other assets. One cannabis-focused mortgage REIT says in its 2025 10-K that it will not hold equity in plant-touching portfolio companies unless they are listed on a national exchange and federal law permits it.
Both models profit from the industry’s limited access to normal capital. Their own filings say so. The mortgage REIT noted that if the NYSE or Nasdaq allowed plant-touching cannabis companies to list, demand for its loans could fall materially. In other words, good news for operators can be competitive pressure for their landlords and lenders. Tenant concentration, state license risk and collateral that is hard to re-lease to non-cannabis users are the other issues to read about.
Cannabis ETFs
Investor.gov describes an exchange-traded fund (ETF) as a registered pooled product whose shares trade on an exchange at market prices. It adds that some ETFs are much less diversified than others. That warning fits cannabis funds closely: a fund labeled “cannabis” may hold a few dozen stocks from a small, volatile industry, and its holdings may be concentrated in a handful of names.
Before buying any cannabis fund, read its prospectus and current holdings for:
- What it actually holds. Canadian producers, ancillary firms, pharmaceutical companies, tobacco companies, REITs, or exposure to U.S. MSOs.
- How it gets U.S. MSO exposure, if at all. Check whether the prospectus describes holding derivatives instead of owning shares directly. Derivatives add counterparty risk and make a fund harder to analyze.
- Costs. The expense ratio, plus trading spreads if the fund is small.
- Concentration. The weight of the top ten holdings.
A fund does not remove industry risk. It spreads company-specific risk across a sector that tends to move together on regulatory news. Our guide to investing fees and taxes explains expense ratios in more detail.
Where the shares trade, and why it matters
The filings of cannabis lenders and operators describe the same constraint: until 2026 the NYSE and Nasdaq had not listed plant-touching cannabis companies, which is why so many MSOs have used the CSE in Canada plus U.S. over-the-counter quotation. OTC trading has real costs for shareholders:
- Clearing and settlement limits. A cannabis property REIT quoted on the OTCQX warned in its 2025 10-K that very few clearing firms will settle trades in its securities. It said this can limit trading volume and push the company toward best-efforts offerings rather than traditional underwritten deals.
- Settlement risk across the border. One MSO’s 2025 10-K warned that Canada’s central securities depository could restrict settlement for companies with U.S. cannabis businesses, which would make its CSE-listed shares very hard to trade.
- Broker access. Check whether your own broker allows trades in a given OTC cannabis security, and at what cost, before you rely on being able to buy or sell.
- Wider spreads and thinner markets. These are common to small and OTC stocks generally. Our article on small-cap and OTC trading risks explains them.
The April 2026 order opened a narrow door. In its quarterly report for the period ended September 30, 2026, one large operator said it had moved its former mixed medical and adult-use operations into a separate company that it no longer controls, redomesticated to Delaware, and listed its shares on the NYSE as a medical-only operator. The same filing describes its remaining interest in the adult-use business as convertible only once the NYSE permits listing companies that consolidate non-medical marijuana operations. That tells you the exchange line still runs between medical and adult-use marijuana. It also shows the kind of corporate restructuring investors should expect to read about in 2026 and 2027 filings.
Two things are worth noting. First, a restructuring like this can move a large part of a company’s revenue out of the listed entity, so compare revenue before and after. Second, a change of listing venue does not change the underlying business risks. The company still depends on state licenses, DEA registration and federal policy.
How this connects to hemp businesses
Hemp companies sit outside the CSA as long as their products meet the federal hemp definition, so they face fewer of these listing and banking barriers. That definition is changing in late 2026, though, and intoxicating hemp products are being pulled back under federal control. Our comparison of hemp and marijuana stocks and our guide to evaluating hemp companies explain the differences.
Frequently asked questions
Are marijuana stocks legal to buy in the U.S.?
Buying publicly quoted shares through a registered broker is a securities transaction, and many U.S. investors hold them. Whether your own broker will execute a trade in a particular OTC cannabis security is a separate question to check. The company’s own legal risk under federal drug law is a business risk you take on as a shareholder.
What is the difference between an MSO and a licensed producer?
An MSO is a U.S. company holding state marijuana licenses in several states. A Canadian licensed producer holds federal Canadian licences under the Cannabis Act. Their legal status, tax treatment and listing options differ.
Did rescheduling make all marijuana companies federally legal?
No. As of November 19, 2026, the April 2026 order covers only FDA-approved drug products and marijuana under state medical licenses. Adult-use marijuana remains in Schedule I while a separate DEA proceeding is pending.
Why do some cannabis companies trade on the CSE?
The Canadian Securities Exchange has listed U.S. operators that U.S. national exchanges would not. Many of those companies also have U.S. OTC quotations so American investors can trade them.
Is a cannabis ETF safer than a single stock?
It reduces exposure to any one company, but not to the industry. Cannabis funds can be concentrated and can use derivatives. Read the prospectus and holdings first.
Rules change quickly in this sector. Check the Federal Register, DEA and each company’s latest SEC filings before relying on any status described here.
Sources
Credit: the facts, figures and rules in this article come from the organizations and authors listed below. All credit for their research and data belongs to them; follow the links to read the originals.
- U.S. Department of Justice / DEA, Final Rule: Rescheduling of FDA-Approved Products Containing Marijuana and State-Licensed Medical Marijuana to Schedule III, 91 FR 22714 (2026)
- DEA, Notice of Hearing on Proposed Rulemaking: Rescheduling of Marijuana (2026)
- DEA, Proposed Rescheduling of Marijuana: Hearing Docket Orders (2026)
- Congressional Research Service, Delay in Changes to Hemp Definition, LSB11496 (2026)
- SEC Office of Investor Education and Advocacy, Investor Alert: Marijuana Investments and Fraud (2018)
- Government of Canada, Justice Laws Website, Cannabis Act (S.C. 2018, c. 16)
- Investor.gov, Exchange-Traded Funds (ETFs)
- Investor.gov, Real Estate Investment Trusts (REITs)
- Trulieve Cannabis Corp., Form 10-K for fiscal year 2025, SEC EDGAR (2026)
- Trulieve Cannabis Corp., Form 10-Q for the quarter ended September 30, 2026, SEC EDGAR (2026)
- Chicago Atlantic Real Estate Finance, Inc., Form 10-K for fiscal year 2025, SEC EDGAR (2026)
- NewLake Capital Partners, Inc., Form 10-K for fiscal year 2025, SEC EDGAR (2026)
Figures last checked: November 19, 2026.
🌱 Finished reading? You earned 5 seeds.
Every article you read to the end earns seeds in Hemp Empire, our free hemp farming tycoon game. Play now →
Some links may be affiliate links. As an Amazon Associate, HempDollars earns from qualifying purchases.


Leave a Reply